ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 3008 participants.

Also called NCT03462498

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 3,008 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03462498
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03462498. Randomized; no masking; primary purpose prevention. Start 2018-04-02 (actual); primary completion 2021-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
Acronym
STOPDAPT-2 ACS
Condition
Acute Coronary Syndrome
Condition
Acute Myocardial Infarction
Condition
Platelet Aggregation Inhibitors
Intervention (Drug)
1-months DAPT
Intervention (Drug)
12-month DAPT
Lead sponsor
Kyoto University, Graduate School of Medicine (class: other)

Record details

Record id
cardio:ct-nct03462498
Content hash
daad7cdd241ee9e5d0dc68f9eb22fc9dc0bdf448b475caf88afd8f9a385477fe